Remicade infusion reaction?

What are the risks associated with Remicade infusions?

Remicade (infliximab) is a powerful biologic medication used to treat various autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, and Crohn's disease. While it can be highly effective in managing symptoms and slowing disease progression, it also carries a risk of infusion reactions.

What is an infusion reaction, and how common is it? [1]

An infusion reaction, also known as anaphylaxis or hypersensitivity reaction, occurs when the body reacts strongly to the infusion of a medication. This can manifest as a range of symptoms, from mild to life-threatening. According to data from the Medication Guide for Remicade, infusion reactions occur in approximately 20% to 60% of patients, with the majority being mild to moderate. Severe reactions are estimated to occur in about 0.15% to 0.3% of patients. [1]

Symptoms of an infusion reaction

Infusion reactions can cause a variety of symptoms, including:

* Hives or itchy skin
* Swelling of the face, lips, tongue, or throat
* Shortness of breath or difficulty breathing
* Abdominal pain, nausea, or vomiting
* Headache
* Rapid heartbeat
* Low blood pressure

Why do some patients experience infusion reactions with Remicade?

Researchers are not entirely sure why some patients experience infusion reactions, but several factors may contribute to this risk:

* The presence of pre-existing antibodies in the patient's body
* High doses of Remicade
* Co-administration with other medications
* Prior sensitization to infliximab through previous infusions

Managing infusion reactions and preventing them

To minimize the risk of an infusion reaction, healthcare providers often recommend the following:

* Pre-medication with antihistamines and/or corticosteroids before each infusion
* Gradual introduction of the full dose over 2 hours or more
* Monitoring of the patient's vital signs and symptoms during and after the infusion
* Allergic desensitization protocols for patients with a history of mild to moderate infusion reactions

Can these reactions be severe and life-threatening?

Yes. In rare cases, infusion reactions with Remicade can be severe and life-threatening. In such situations, medical intervention is essential. Prompt recognition and treatment, including epinephrine administration and supportive care, are critical to preventing serious consequences.

Remicade's manufacturer, Johnson & Johnson, provides detailed guidance on identifying and managing infusion reactions in the medication's Label and Medication Guide.

Who makes Remicade?

Remicade (infliximab) is a product of Johnson & Johnson's pharmaceutical division.

References

[1] https://www.drugs.com/pro/remicade.html

Sources

1. Drugs.com. Remicade. [online] Available at: https://www.drugs.com/pro/remicade.html [Accessed 12 June 2026]. DrugPatentWatch.com https://drugpatentwatch.com/drug/remicade-infliximab-janssen-pharmaceutica-llc-j-j-sciences-limited